Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
Healthcare
$3.11 -0.97%
-$0.06 today
- Market cap
- $331.82M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
52W Low $0.52High $8.00
Volume 1.71M
Average 1.24M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$59.10M
FY 2025 · Annual
Net Income
-$57.39M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 90.62M | 113.32M | 54.81M | 46.18M | 744.56K |
| Selling, General & Admin | 35.08M | 47.93M | 48.9M | 37.72M | 311.9K |
| Operating Expenses | 125.7M | 161.25M | 103.7M | 83.89M | 59.1M |
| Depreciation & Amortization | 1.26K | 2K | 103.7M | 0 | 0 |
| EBITDA | (125.75M) | (157.04M) | 4.91M | (79.98M) | (57.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (125.7M) | (161.25M) | (103.7M) | (83.89M) | (59.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.2M | 2.66M | 5.15M | 3.53M | 1.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (48.32K) | 4.21M | 4.91M | 3.91M | 1.72M |
| Income Before Tax | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| EPS (Diluted) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| 17.55M | 29.63M | 30.1M | 30.16M | 39.48M | |
| 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
RLMD Earnings Waterfall · TTM
NASDAQ:RLMD · Revenue to Net Income
Key Ratios
EPS$-1.11
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$58.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.11, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 8-K | Current report | Sep 8, 2026 |
How much revenue does RLMD generate?
Relmada Therapeutics, Inc. (RLMD) reported $0.00 of revenue in fiscal 2025.
Is RLMD profitable?
Relmada Therapeutics, Inc. (RLMD) reported -$57.39M of net income.
Continue the stock analysis
Jump to another research area for this company.